Cell type-specific adenoviral transgene expression in the intact ovine pituitary gland after stereotaxic delivery: An in vivo system for long-term multiple parameter evaluation of human pituitary gene therapy

Endocrinology

Volumn 142, Issue 2, 2001, Pages 795-801

  Davis, J R E ^a   McVerry, J ^a   Lincoln, G A ^a   Windeatt, S ^a   Lowenstein, P R ^a   Castro, M G ^a   McNeilly, A S ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL SPECIFICITY; CELL TYPE; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; HORMONE BLOOD LEVEL; HYPOPHYSIS; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; SHEEP; SIGNAL TRANSDUCTION; TRANSGENE;

EID: 0035105851     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.142.2.7963     Document Type: Article

References (30)

1. The cytogenesis and pathogenesis of pituitary adenomas
2. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience
3. Hypopituitarism following external radiotherapy for pituitary tumours in adults
4. Management of prolactinomas
5. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy
6. Multistep signaling requirements for pituitary organogenesis in vivo
7. Expression of transgenes in normal and neoplastic anterior pituitary cells using recombinant adenoviruses: Long term expression, cell cycle dependency, and effects on hormone secretion
8. High efficiency method for gene transfer in normal pituitary gonadotropes: Adenoviral-mediated expression of G protein-coupled receptor kinase 2 supresses luteinizing hormone secretion
9. Targeted expression of toxic genes directed by pituitary hormone promoters: A potential strategy for adenovirus-mediated gene therapy of pituitary tumors
10. Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas
11. Transcriptional targeting to anterior pituitary lactotrophic cells using recombinant adenovirus vectors in vitro and in vivo in normal and estrogen/sulpiride-induced hyperplasic anterior pituitaries
12. Multihormonal regulation of the human prolactin gene-expression from 5000bp of its upstream sequence
13. Pit-1 binding sequences permit calcium regulation of human prolactin gene expression
14. Dynamic changes in prlactin promoter activation in individual living lactotrophic cells
15. Stereotaxic approach to hypothalamic nuclei of the Shiba goat with radiographic monitoring
16. Encephalic ventricles of the ewe (Ovis aries L.): Conformation, relations and stereotaxic topography
17. Detection of prolactin gene expression in the sheep pituitary gland and visualization of the specific translation of the signal in gonadotrophs
18. Effect of suppression of plasma prolactin on ovulation, plasma gonadotrophins and corpus luteum function in LH-RHtreated anoestrous ewes
19. Suppression of pulsatile luteinizing hormone secretion by gonadotrophin-releasing hormone antagonist does not affect episodic progesterone secretion or corpus luteum function in ewes
20. Effect of chronic immunoneutralization of thyrotropin-releasing hormone
21. Sheep adrenal inhibin
22. Gene therapy for pituitary tumours
23. Regulatory elements controlling the expression of the human prolactin gene
24. Stereotactic injection of adenoviral vectors that target gene expression to specific pituitary cell types: Implication for gene therapy
25. Gene therapy strategies for the treatment of pituitary tumours
26. Adenovirus-mediated inducible gene expression through tetracycline-controllable transactivator with nuclear localization signal
27. Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system
28. Cell-type specific expression in the pituitary: Physiology and gene therapy
29. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials
30. Central nervous toxicity of two adenoviral vectors encoding variants of the herpes simplex virus type 1 thymidine kinase: Reduced cytotoxicity of a truncated HSV-1 TK